2024-11-24 - Analysis Report
## Colgate-Palmolive Co (CL) Stock Analysis Report

**1. Performance Comparison and Divergence:**

Colgate-Palmolive (CL) is a multinational consumer goods company specializing in oral hygiene, personal care, and household products.  The cumulative return of CL is 47.68%, while the S&P 500 (VOO) shows a cumulative return of 127.58%.  This represents a significant underperformance of CL against the benchmark, with a difference of -79.9%.  The relative divergence of -79.9 places it at the 7.07 percentile of its historical range of divergence (max: 7.22, min: -86.53), indicating a relatively low performance compared to its historical track record against the S&P 500.

**Alpha and Beta Analysis:**

| Year       | CAGR  | MDD   | Alpha | Beta | Cap(B) |
|------------|-------|-------|-------|-------|--------|
| 2015-2017  | 16.8% | 12.6% | -21.6% | 0.7   | 61.6   |
| 2016-2018  | -1.5% | 14.1% | -33.8% | 0.5   | 48.6   |
| 2017-2019  | 12.8% | 14.1% | -38.9% | 0.5   | 56.2   |
| 2018-2020  | 22.4% | 21.6% | -25.0% | 0.6   | 69.9   |
| 2019-2021  | 54.7% | 21.6% | -45.4% | 0.6   | 69.7   |
| 2020-2022  | 24.1% | 21.6% | 0.5%  | 0.6   | 64.4   |
| 2021-2023  | 1.6%  | 16.4% | -33.4% | 0.3   | 65.1   |
| 2022-2024  | 20.5% | 16.4% | -9.6%  | 0.3   | 77.0   |

The Alpha values suggest periods of underperformance relative to the market. Beta generally indicates moderate market sensitivity.  Note that the provided Alpha values seem inconsistent with the CAGR.  Further investigation into the calculation methodology is needed.


**2. Recent Price Movement:**

* **Closing Price:** $94.92
* **5-day Moving Average:** $94.26
* **20-day Moving Average:** $93.22
* **60-day Moving Average:** $99.31

The price is currently below its 60-day moving average, suggesting a possible downtrend.  The proximity to the 5- and 20-day moving averages indicates some short-term price stability.


**3. Technical Indicators and Expected Return:**

* **RSI:** 54.55 (Slightly above neutral; neither overbought nor oversold)
* **PPO:** 0.61 (Positive, suggesting bullish momentum)
* **20-Day Relative Divergence Change:** -0.81 (Indicates a recent short-term downturn)
* **Expected Return (2+ years):** 0.0%  This implies no significant outperformance relative to the S&P 500 is expected over a long-term investment horizon, based on the current data.  This needs to be viewed in conjunction with the historical underperformance.

The current price of $94.92 doesn't signal a significant price spike (up or down) based on the provided data.


**4. Recent Financial Performance and Outlook:**

| Date       | EPS   | Revenue       |
|------------|-------|----------------|
| 2024-10-25 | 0.9   | $5.03B         |
| 2024-07-26 | 0.89  | $5.06B         |
| 2024-04-26 | 0.83  | $5.07B         |
| 2023-10-27 | 0.86  | $4.92B         |
| 2024-10-25 | 0.86  | $4.92B         |

There appears to be a slight but consistent increase in EPS and relatively stable revenue.  The repetition of the 2023-10-27 data point needs clarification.  Analyst estimates for the latest earnings should be incorporated for a more comprehensive view.


**6. Financial Information Analysis:**

**1) Revenue and Profitability:** Revenue remains relatively stable, with profit margins consistently high (around 60%).

**2) Capital and Profitability:** ROE shows significant fluctuations, which requires further investigation to understand the underlying causes.  Negative equity in one quarter is concerning and demands further analysis of the balance sheet and cash flow statements.


**7. News and Recent Issues:**

* **Recent Earnings News:**  Information from sources like Shacknews or similar financial news sites for the last two days is needed to assess recent news impacting CL.
* **Market Outlook:**  A review of recent analyst reports from sources like Finbold will provide further insight into the current market sentiment surrounding CL.

**Missing Information:** Crucial information is lacking, including details about specific analyst opinions, recent news, and the consensus EPS estimates for the latest quarter.  This prevents a comprehensive analysis.


**8. Summary of Analysis:**

Colgate-Palmolive (CL) has underperformed the S&P 500 significantly over the given historical period. While recent financial results show stable revenue and relatively consistent EPS growth, the substantial underperformance relative to the market, erratic ROE, and the presence of negative equity in one quarter raise serious concerns. The technical indicators offer a mixed signal, and the lack of recent news and analyst opinions hinders a conclusive assessment.  More detailed information, particularly the analyst consensus estimates and recent news affecting CL, is critical for a thorough evaluation.  The provided Alpha values require reconciliation with the CAGR figures.  An in-depth analysis of the balance sheet and cash flow statements is recommended to address the inconsistencies in the ROE data and negative equity.


**9. Disclaimer:** This analysis is based on the limited information provided.  It is not financial advice and should not be used as a basis for investment decisions.  Conduct thorough due diligence and consult with a qualified financial advisor before making any investment choices.
